Valion Bio, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
Valion Bio shows severe financial deterioration with cash declining 43% to $7.2M, net loss increasing 23% to $6.4M, and stockholders' equity falling 34% to $11.1M. The company faces significant liquidity concerns with substantial operating lease obligations and convertible debt, while expanding inventory suggests new operational commitments without demonstrated revenue generation.
Red Flags Detected (7)
Cash and equivalents declined 43% from $12.6M to $7.2M in just one quarter
Accumulated deficit increased from $52.6M to $59.0M, indicating $6.4M quarterly loss
Stockholders' equity dropped 34% from $16.8M to $11.1M
4 more red flags detected
Key Takeaways
Company transformed from Tivic Health Systems to Valion Bio, indicating strategic pivot
Rapid cash depletion suggests urgent need for additional financing
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.